Pipeline news

• Syndax Announces Proposed Public Offering of Common Stock

  29 April 2020

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering. All of the shares in the proposed offering are to be sold by Syndax.

• binx health Announces Second FDA 510(k) Clearance of its Molecular Point-of-Care Infectious Disease Platform

  29 April 2020

  

  binx health, a leader in infectious disease testing solutions, announced that it has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) in one of the largest markets for infectious disease testing. Today, the Company announces FDA 510(k) clearance to market its sensitive and specific, molecular point-of-care testing platform, the binx io, for the detection of chlamydia (CT) and gonorrhea (NG)—the two most tested-for STIs globally—in male urine specimens. The Company previously announced, in August of 2019, FDA 510(k) clearance of the binx io for use with clinician and self-collected vaginal swab specimens.

• Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE™ Commercial Partnership with Bausch Health

  28 April 2020

  

  Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today an update to the XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) New Drug Application (NDA) resubmission timeline and to its commercialization and development partnership with Bausch Health Companies Inc. (“Bausch Health”) and Bausch + Lomb, its leading global eye health business.

• Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias

  27 April 2020

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presents preclinical and initial clinical data for SNDX-5613, the Company's potent, highly selective oral menin inhibitor.

• Clearside Biomedical Appoints Nancy J. Hutson, Ph.D. to its Board of Directors

  22 April 2020

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that  Nancy J. Hutson , Ph.D. has been appointed to the Company's Board of Directors, effective  April 21, 2020.

• Clearside Biomedical Establishes Scientific Advisory Board with Distinguished Retinal Physicians

  09 April 2020

  

  Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the formation of a  Scientific Advisory Board  comprised of world-renowned retinal physicians to advise on the Company’s research and development programs. 

• Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results

  18 March 2020

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2019.

• Clearside Biomedical Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

  11 March 2020

  

  Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the fourth quarter and year ended  December 31, 2019  and provided a corporate update.

• Clearside Biomedical Announces License Agreement with Arctic Vision for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China and South Korea

  11 March 2020

  

  Clearside Biomedical , Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Arctic Vision, a company focused on developing and commercializing innovative ophthalmology therapies in  China  and  Asia , has acquired an exclusive license for the commercialization and development of XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China (mainland  China ,  Hong Kong ,  Macau  and  Taiwan ) and  South Korea .

• Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officer

  11 March 2020

  

  Clearside Biomedical , Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., has been appointed President and Chief Executive Officer. He will continue to serve on the Board of Directors. This appointment was effective  March 1, 2020.